Table 2.

Cox regression analyses of the various factors associated with event-free survival and overall survival in neuroblastoma patients without MYCN (n = 52)

Event-free survival
Variables	HR (95% CI)	Favorable/Unfavorable	P
Univariate analysis
Stage	2.66 (0.77–9.17)	1, 2, 3, 4S/4	0.123
Gender	3.66 (0.78–7.26)	Female/Male	0.102
Risk	4.45 (1.25–15.77)	Low, Middle/High	0.021
Age at diagnosis_1.5	14.03 (2.97–66.36)	<1.5 years/≧1.5 years	0.001
Dicer	12.20 (2.57–57.82)	High/Low	0.002
Drosha	5.48 (1.16–25.84)	High/Low	0.032
Multivariate analysis
Age at diagnosis_1.5	9.72 (1.37–69.10)	<1.5 years/≧1.5 years	0.023
Dicer	1.88 (0.22–16.23)	High/Low	0.568
Drosha	4.12 (0.69–24.68)	High/Low	0.121
Overall survival
Variables	HR (95% CI)	Favorable/Unfavorable	P
Univariate analysis
Stage	5.86 (1.07–32.06)	1, 2, 3, 4S/4	0.041
Gender	4.06 (0.47–34.81)	Female/Male	0.648
Risk	16.32 (1.90–139.92)	Low, Middle/High	0.011
Age at diagnosis*	594.6 (0.01–∞)	<1.5 years/≧1.5 years	0.242
Dicer	13.39 (1.56–114.77)	High/Low	0.018
Drosha	2.51 (0.46–13.74)	High/Low	0.288
Multivariate analysis
Stage	3.22 (0.56–18.55)	1, 2, 3, 4S/4	0.190
Dicer	9.60 (1.05–87.44)	High/Low	0.045

Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval.

^*Because there was no death among the patients with diagnosis less than 1.5 years or 1 year.